Treatment of HHV-6 Encephalitis in Immunocompetent Children
Intravenous foscarnet or ganciclovir is recommended as first-line treatment for HHV-6 encephalitis in immunocompetent children, with drug selection based on side effect profiles and patient comorbidities. 1
First-Line Treatment Options
Foscarnet
- Dosage: 90 mg/kg twice daily (180 mg/kg/day) 1
- Advantages: Associated with lower 30-day mortality compared to ganciclovir in transplant patients 1
- Disadvantages: Nephrotoxicity, electrolyte disturbances
Ganciclovir
- Dosage: 5 mg/kg twice daily (10 mg/kg/day) 1
- Disadvantages: Myelosuppression (bone marrow toxicity)
- Case evidence: Successfully used at high doses (18 mg/kg/day) in an immunocompetent child with severe HHV-6 encephalitis 2
Treatment Duration and Monitoring
- Treat for at least 3 weeks 1
- Continue until HHV-6 DNA is cleared from blood and, if possible, CSF 1
- Monitor renal function during treatment due to potential nephrotoxicity, particularly with foscarnet 3
Alternative and Adjunctive Approaches
- Combination therapy: Combined ganciclovir and foscarnet can be considered in severe cases, with one study showing 100% response rate, though sample size was small 1
- Immunosuppressive medication: If applicable, reduce immunosuppressive medications when possible 1
Diagnostic Considerations
- MRI should be performed as soon as possible in all patients 4
- CSF PCR for HHV-6 is essential for diagnosis 4
- Consider testing for other neurotropic viruses (HSV 1 & 2, VZV, enteroviruses) 4
Clinical Pearls and Pitfalls
- Pitfall: Delaying treatment while awaiting confirmatory tests in severely ill patients
- Pearl: Full-dose therapy (foscarnet ≥180 mg/kg/day or ganciclovir ≥10 mg/kg/day) is associated with significantly better response rates than lower doses 1
- Pitfall: Inadequate treatment duration - ensure minimum 3-week course and clearance of viral DNA from CSF
- Pearl: Consider HHV-6 encephalitis in children with altered mental status, seizures, memory changes, or specific visual hallucinations 5
Special Considerations
- While most guidelines focus on immunocompromised patients, case reports demonstrate successful treatment of HHV-6 encephalitis in immunocompetent children with ganciclovir 2, 6
- Long-term follow-up is important as neurological sequelae may include epilepsy and ataxia despite good initial recovery 2
- There are insufficient data on the use of cidofovir for HHV-6 encephalitis to make a recommendation 1
Treatment Algorithm
- Confirm diagnosis with CSF PCR for HHV-6
- Initiate intravenous antiviral therapy immediately upon strong suspicion
- Choose between foscarnet (90 mg/kg twice daily) or ganciclovir (5 mg/kg twice daily) based on patient's renal function and hematologic status
- Continue treatment for minimum 3 weeks
- Monitor for clearance of HHV-6 DNA from blood and CSF
- Consider combination therapy in severe cases or if response is inadequate
- Monitor for treatment-related toxicities (renal function, electrolytes, blood counts)